Description

SILDIGRA 120 MG (1X5)

Indications

SILDIGRA 120 MG is primarily indicated for the treatment of erectile dysfunction (ED) in adult men. Erectile dysfunction is a condition characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. SILDIGRA is effective in enhancing erectile function when sexual stimulation occurs. It is important to note that SILDIGRA does not cure erectile dysfunction or increase sexual desire, but rather facilitates the physiological process of erection in response to sexual arousal.

Mechanism of Action

The active ingredient in SILDIGRA is sildenafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor. Sildenafil works by blocking the action of PDE5, an enzyme that breaks down cyclic guanosine monophosphate (cGMP), a molecule that plays a crucial role in the relaxation of smooth muscle and vasodilation in the corpus cavernosum of the penis. When sexual stimulation occurs, nitric oxide (NO) is released, leading to an increase in cGMP levels. By inhibiting PDE5, SILDIGRA enhances and prolongs the effects of cGMP, resulting in improved blood flow to the penis and facilitating the achievement of an erection.

Pharmacological Properties

SILDIGRA is rapidly absorbed after oral administration, with peak plasma concentrations typically occurring within 30 to 120 minutes. The bioavailability of sildenafil is approximately 40%, and its effects can last for up to four hours, although the duration may vary based on individual factors. The drug is metabolized primarily in the liver by cytochrome P450 enzymes, particularly CYP3A4, and is excreted in the urine. The pharmacokinetics of SILDIGRA can be influenced by factors such as age, liver function, and concurrent use of other medications.

Contraindications

SILDIGRA is contraindicated in patients who are hypersensitive to sildenafil or any of its components. It should not be used in conjunction with nitrates or nitric oxide donors, as this combination can lead to a significant drop in blood pressure. Additionally, individuals with severe cardiovascular disorders, such as unstable angina, recent history of myocardial infarction, or severe heart failure, should avoid using SILDIGRA. Patients with severe hepatic impairment or those undergoing dialysis should also refrain from using this medication.

Side Effects

Common side effects associated with SILDIGRA include headache, flushing, dyspepsia, nasal congestion, dizziness, and visual disturbances such as changes in color perception. While most side effects are mild to moderate in intensity, serious adverse reactions can occur, including priapism (prolonged and painful erection), sudden vision loss, and sudden hearing loss. Patients experiencing any severe side effects should seek immediate medical attention. It is important to discuss potential risks and benefits with a healthcare provider before starting treatment with SILDIGRA.

Dosage and Administration

The recommended starting dose of SILDIGRA is 50 mg, taken approximately one hour before sexual activity. Based on efficacy and tolerability, the dose may be adjusted to 100 mg or decreased to 25 mg. The maximum recommended dosing frequency is once per day. SILDIGRA can be taken with or without food; however, high-fat meals may delay the onset of action. Patients should follow their healthcare provider’s instructions regarding dosage and administration to ensure optimal results and minimize the risk of adverse effects.

Interactions

SILDIGRA may interact with various medications, leading to potential adverse effects or reduced efficacy. Co-administration with nitrates can cause significant hypotension and is contraindicated. Caution should be exercised when using SILDIGRA with other medications that affect the CYP3A4 enzyme, such as certain antifungals (e.g., ketoconazole), antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir). Additionally, medications that lower blood pressure may enhance the hypotensive effects of SILDIGRA. Patients should inform their healthcare provider about all medications they are taking to avoid potential interactions.

Precautions

Before starting SILDIGRA, patients should undergo a thorough medical evaluation to assess their cardiovascular health and any underlying conditions that may contraindicate its use. Caution is advised in patients with anatomical deformities of the penis, conditions that predispose them to priapism, or those with a history of stroke or severe liver disease. Patients should also be aware of the potential for visual disturbances and should discontinue use if they experience sudden vision loss. Regular follow-up with a healthcare provider is recommended to monitor the effectiveness and safety of the treatment.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy and safety of sildenafil in treating erectile dysfunction. In a randomized, double-blind, placebo-controlled trial, men with varying degrees of ED reported significant improvements in erectile function after using sildenafil compared to placebo. The studies indicated that sildenafil is effective across different age groups and levels of ED severity, with a favorable safety profile. Long-term studies have also shown sustained efficacy and safety over extended periods of use, reinforcing the role of sildenafil as a first-line treatment for ED.

Conclusion

SILDIGRA 120 MG is an effective treatment option for men experiencing erectile dysfunction. Its mechanism of action as a PDE5 inhibitor enhances blood flow to the penis, facilitating the achievement and maintenance of an erection during sexual stimulation. While generally well-tolerated, it is essential for patients to be aware of potential side effects, contraindications, and drug interactions. A thorough consultation with a healthcare provider is crucial to ensure safe and effective use of SILDIGRA. With appropriate medical guidance, SILDIGRA can significantly improve the quality of life for men suffering from erectile dysfunction.